Vivo Opportunity Fund Holdings sells Soleno Therapeutics stock worth over $49m By Investing.com

In a series of transactions, Vivo Opportunity Fund Holdings, L.P., a significant shareholder in Soleno Therapeutics Inc. (NASDAQ:), has sold a substantial portion of its holdings in the company. The transactions, which took place over three consecutive days, resulted in the sale of 1,025,000 shares of common stock, with the total value exceeding $49 million.

On the first day, 500,000 shares were sold at an average price of $48.73 per share, followed by a sale of 425,000 shares at an average price of $47.35 on the second day. The final day saw a smaller transaction of 100,000 shares, with an average price of $47.22 per share. The sales were made on the open market, with prices ranging from $46.47 to $51.17 across the various transactions.

After these sales, Vivo Opportunity Fund Holdings’ stake in Soleno Therapeutics decreased, but the entity still holds a significant number of shares, with 6,291,851 shares remaining in its possession. The sales were conducted indirectly by Vivo Opportunity Fund Holdings, with Vivo Opportunity, LLC acting as the general partner.

The transactions were disclosed in compliance with SEC regulations, which require insiders and significant shareholders to report sales and purchases of company stock. The disclosed prices represent weighted averages, and the actual sale prices varied within the ranges provided in the filing footnotes.

Investors and market watchers often scrutinize such transactions for insights into insider perspectives on a company’s financial health and future prospects. Soleno Therapeutics, a company specializing in electromedical and electrotherapeutic apparatus, has thus seen a notable change in its ownership structure following these transactions.

In other recent news, Soleno Therapeutics has made significant progress with its New Drug Application (NDA) for DCCR, a treatment for Prader-Willi syndrome. The FDA has granted the application Priority Review status, indicating a recognition of the unmet medical need. This development has been welcomed by Stifel and Oppenheimer, both of which have maintained a positive rating on the company’s stock, citing potential market opportunities and robust future sales projections.

The FDA’s acceptance of the NDA is accompanied by plans for an advisory committee meeting, expected to further bolster the case for DCCR. This meeting marks a significant milestone for Soleno Therapeutics as it moves closer to potentially bringing this innovative treatment to market. The company has also seen changes in its Board of Directors, with Matthew Pauls stepping in as the new Lead Independent Director and biotech veteran Dawn Carter Bir joining the board.

Soleno Therapeutics has entered an agreement with Jefferies LLC to potentially sell up to $150 million of its common stock, aiming to bolster its financial flexibility. Additionally, the company has awarded performance-based restricted stock units to its employees, aligning their interests with the company’s performance. These are among the recent developments in Soleno Therapeutics’ ongoing operational and strategic initiatives.

InvestingPro Insights

Amid the notable changes in ownership for Soleno Therapeutics Inc. (NASDAQ:SLNO), investors may find value in considering the company’s financial metrics and analyst expectations. With a market capitalization of approximately $1.81 billion, Soleno Therapeutics has been navigating the market with some distinctive financial characteristics.

One InvestingPro Tip highlights that Soleno Therapeutics holds more cash than debt on its balance sheet, which can be an indicator of financial stability and flexibility. Additionally, analysts predict that the company will be profitable this year, which could signal a turning point for Soleno after not being profitable over the last twelve months.

InvestingPro Data reflects a mixed financial picture. The Price / Book ratio as of the last twelve months leading up to Q2 2024 stands at 6.45, which suggests that the company is trading at a higher value compared to its book value. Furthermore, the company has experienced a staggering one-year price total return of 767.13%, demonstrating significant investor confidence and stock performance within that period.

For those interested in a deeper analysis, InvestingPro offers additional insights. There are 9 more InvestingPro Tips available for Soleno Therapeutics, which investors can explore for a comprehensive understanding of the company’s financial health and market position. These tips can be accessed through the dedicated InvestingPro page for Soleno Therapeutics at https://www.investing.com/pro/SLNO.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.